Key facts
- BioPhy’s last known valuation is $20.0M (Mar 2025).
- It has raised $5.9M across 1 recorded rounds; the latest was Early Stage VC ($6.6M) in Mar 2025.
- BioPhy has filed 1 Form D with the SEC, most recently Mar 2025 ($6.6M sold to 56 investors).
- Status: Acquired/Merged.
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for BioPhy
Funding rounds
1 roundsAbout BioPhy
Developer of an artificial intelligence technology designed to optimize global pharmaceutical operations. The company offers a predictive and generative platform that rapidly analyzes clinical trial data to forecast study outcomes accurately and provides on-demand scientific and clinical guidance, enabling healthcare experts to enhance manufacturing and productivity across regulatory, quality, and operational workflows through intelligent automation and data-driven decision-making.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2019
- Employees
- 15
- Website
- biophy.ai/
- Ownership
- Acquired/Merged
BioPhy doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioPhy shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioPhy in its N-PORT filings yet. We sweep new filings monthly.